Solstice Biologics Raises $18M

San Francisco-based Soltice Biologics said Friday that it has raised $18M in a Series A funding round. The firm, which is developing technology that enables the delivery of RNA-based therapeutics across membranes, said the funding was led by venBio and also included Aeris Capital. The firm's technology is aimed at helping improve the therapeutic potential of RNA interference (RNAi) and microRNA. The firm's technology was licensed from the University of California, San Diego. More information »